Roche convinces NICE to add 'incremental' Tarceva as NSCLC treatment option
This article was originally published in Scrip
Executive Summary
Roche's Tarceva (erlotinib) looks set to join AstraZeneca's Iressa (gefitinib) in England and Wales as An NHS-funded first-line option for patients with locally advanced or metastatic EFGR mutation-positive non small-cell lung cancer. An updated economic model convinced NICE, the health technology appraisal institute, to recommend the drug after it was initially unsure why it should recommend an alternative to Iressa.